Video

NCCN 2024 Prostate Cancer Guidelines Update VL

Search

NCCN 2024 Prostate Cancer Guideline Updates: Progressive M0 CSPC Management - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen dive into the 2024 updates of the NCCN prostate cancer guidelines, specifically addressing the treatment and monitoring of progressive M0 CSPC in patients post-maximal pelvic therapy. Highlighting the critical nature of identifying high-risk patients, they introduce the major shift in recommendations based on the EMBARK trial results, which supports considering enza...
Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
NCCN 2024 Guidelines Endorse Novel Prostate Test for Precision Risk Stratification - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification in prostate cancer management. This innovative test, now considered a predictive model, marks a significant advance, providing more accurate risk assessments for biochemical recurrence, distant metastasis, and prostate can...